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Abstract: Chikungunya virus is a mosquito-borne emerg-
ing pathogen that has a major health impact in humans
and causes fever disease, headache, rash, nausea,
vomiting, myalgia, and arthralgia. Indigenous to tropical
Africa, recent large outbreaks have been reported in parts
of South East Asia and several of its neighboring islands in
2005–07 and in Europe in 2007. Furthermore, positive
cases have been confirmed in the United States in
travelers returning from known outbreak areas. Currently,
there is no vaccine or antiviral treatment. With the threat
of an emerging global pandemic, the peculiar problems
associated with the more immediate and seasonal
epidemics warrant the development of an effective
vaccine. In this review, we summarize the evidence
supporting these concepts.
Introduction
Chikungunya virus (CHIKV), a mosquito-borne pathogen listed
by National Institute of Allergy and Infectious Diseases (NIAID) as
a Category C Priority Pathogen that causes Chikungunya fever
(CHIKF), has been spreading throughout Asia, Africa, and parts
of Europe in recent times [1,2,3]. CHIKV is an arthropod-borne
virus (arbovirus) and is transmitted to humans primarily by Aedes
aegypti, the infamous yellow fever propagator [4,5]. CHIKV
infection is marked by severe joint pain, contorting its victims into
unusual postures [6]. The disease gets its name from the
Kimakonde vernacular language of Tanzania and Mozambique,
and the word chikungunya means ‘‘that which contorts or bends
up’’ and translates in Swahili to ‘‘the illness of the bended walker’’
[7,8,9]. In Africa, CHIKV is maintained in a sylvatic cycle among
forest-dwelling Aedes spp. mosquitoes, wild primates, squirrels,
birds, and rodents (Figure 1) [10]. In Asia, the disease is vectored
by Ae. aegypti and Ae. albopictus [11]. Transmission in Asia occurs in
an urban cycle whereby the mosquito spreads the disease from an
infected human to an uninfected human, following an epidemi-
ological pattern similar to dengue fever [12].
The 2005–2006 epidemic of CHIKV in La Reunion islands in
the Indian Ocean, spurred the discovery of a new vector species,
Ae. albopictus [5]. Wrecking over one-third of the island’s
population, this epidemic peaked its devastation between January
and February 2006, when over 46,000 cases came into light every
week, including 284 deaths [5,13]. Ae. albopictus is common in
urban areas of the United States and is already flourishing in 36
states, raising grave concerns to the immunologically naive
populace of the United States [14].
Accordingly, this review elaborately details the epidemiology
and global expansion of CHIKV, describes its clinical features and
pathogenesis and its symptoms and complications, and finally
nominates a possible vaccine approach against CHIKV infection.
CHIKV Emergence
CHIKV has been isolated into three genotypes based on
phylogenetic studies. These genotypes, based on the gene
sequences of an Envelope protein (E1), are Asian, East/Central/
South African, and West African [4,11,15]. Using phylogenetic
models, Cherian et al. estimate that the Asian genotype of CHIKV
emerged between 50 and 310 y ago, and the West and East
African genotypes diverged between 100 and 840 y ago [15].
Since then, CHIKV has come a long way, with several mutations
incorporated, and has continued to wreak epidemics in several
regions. Recent activities of CHIKV include the Indian epidemic
in 2005–2006, which was followed by a sudden explosion of cases
in 2007. An estimated 1.3 million people across 13 states were
reported to be infected in India [12,16], and CHIKV was also
widespread in Malaysia, Sri Lanka, and Indonesia [17]. In July–
August of 2007, CHIKV was reported in Italy, probably brought
in by travelers from CHIKV-prone regions of India, Africa, and
Indian Ocean islands such as Mauritius, Madagascar, and
Seychelles. Few of the Italian isolates were found to have evolved
from the Kerala isolate, which was associated with a A226V shift
in E1 gene that represents a successful evolutionary adaptation in
the mosquito vector similar to the ones observed in Reunion Island
[2,18,19].
In recent times, with an increase in global travel, the risk for
spreading CHIKV to non-endemic regions has heightened [1].
Several travelers have brought CHIKV home with them after
visiting areas with actively infected populations [12,20]. Such cases
have been documented in European countries, Australia, Asia,
and the United States [8,21]. The United States has already
reported at least twelve cases of travel-associated CHIKV, while
France has reported 850 cases, and the United Kingdom 93
[8,14]. Beyond this, CHIKV-infected travelers have also been
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www.plosntds.org 1 April 2010 | Volume 4 | Issue 4 | e623diagnosed in Australia, Belgium, Canada, Czech Republic, French
Guiana, Germany, Hong Kong, Italy, Japan, Kenya, Malaysia,
Martinique, Norway, Switzerland, and Sri Lanka [21]. Some
travelers were viremic, worrying public health officials about the
spread of CHIKV to new areas [1,8].
Symptoms and Complications
The incubation time for CHIKV is relatively short, requiring
only 2–6 d with symptoms usually appearing 4–7 d post-infection
[22]. Vazeille et al. detected CHIKV in the salivary glands of Ae.
albopictus only 2 d after infection [5]. Upon infection, CHIKF
tends to present itself in two phases. The first stage is acute, while
the second stage, experienced by most but not all, is persistent,
causing disabling polyarthritis. Characteristics of the acute phase
include an abrupt onset of fever, arthralgia, and in some cases,
maculopapular rash [6,23]. The acute phase causes such intense
joint and muscular pain that makes movement very difficult and
prostrates its victims [6,20].
Ninety-five percent of infected adults are symptomatic after
infection, and of these, most become disabled for weeks to months
as a result of decreased dexterity, loss of mobility, and delayed
reaction. Eighteen months after disease onset, 40% of patients are
found to still have anti-CHIKV IgM [6,18,23,24]. The chronic
stage of CHIKF is characterized by polyarthralgia that can last
from weeks to years beyond the acute stage [6]. CHIKV has been
shown to attack fibroblasts, explaining the involvement of muscles,
joints, and skin connective tissues. The high number of nociceptive
nerve endings found within the joints and muscle connective
tissues can explain pain associated with CHIKF [25,26].
More than 50% of patients who suffer from severe CHIKF are
over 65 y old, and more than 33% of them die. Most adults who
suffer from severe CHIKF have underlying medical conditions
[6,24,27]. The other group that is disproportionately affected
by severe CHIKV is children. Other complications associated
with CHIKV, from most common to least common, include
respiratory failure, cardiovascular decompensation, meningoen-
cephalitis, severe acute hepatitis, severe cutaneous effects,
other central nervous system problems, and kidney failure
[6,18,20,23,24,26,27].
CHIKV Viral Mutation and Resulting Increase in
Epidemic Potential
CHIKV undertakes a complex replication cycle upon host
infection (Figure 2), which makes its genome susceptible to
mutations [28,29]. For instance, Ae. aegypti, responsible for
epidemics in Kenya, Comoros, and Seychelles, carried CHIKV
with an alanine in the 226 position of the E1 gene (E1-A226)
[4,18]. However, when the virus struck La Reunion Islands, a
decline in population of Ae. aegypti, due to massive dichlorodiphe-
nyltrichloroethane usage and dearth of Ae. albopictus species’
Figure 1. Life cycle of Chikungunya virus in Africa showing the interconnection between the sylvatic cycle on the left and the urban
cycle on the right. Particularly in Africa, the virus is maintained in a sylvatic cycle comprising non-human primates and different species of forest-
dwelling mosquitoes including Aedene mosquitoes (Ae. Africanus, Ae. furcifer-taylori, Ae. dalzieli, etc.,) and non Aedene mosquitoes (Mansonia, Culex,
etc.) [10].
doi:10.1371/journal.pntd.0000623.g001
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ment of alanine at position 226 with valine (E1-A226V) [5]. This
mutation allowed CHIKV’s secondary vector species, Ae. albopictus,
to supplement Ae. aegypti as its primary vector [5].
Within a year, the E1-A226V mutation was present in La
Reunion Island, and Ae. albopictus apparently vectored the large
epidemic infecting 34% of La Reunion Island’s population [5]. All
of the CHIKV strains isolated from Mayotte carried the E1-
A226V mutation, and the mutation was also found in Madagascar
in 2007 [5]. The E1-A226V mutation was not present at the
beginning of the Indian Ocean Islands outbreak (before Septem-
ber 2005). However, more than 90% of later viral strains found
there had incorporated the mutation (December–March 2006),
indicating a genotype switch during the winter season [5,18,20].
The E1-A226V mutation also enabled an increase in infectivity
of Ae. albopictus when compared to its infectivity of Ae. aegypti
[4,11,18,30], and with several factors taken together, Ae. albopictus
has become the new preferred and more lethal vector for CHIKV
[4,5,11]. In fact, Tsetsarkin et al. found that a Green Fluorescent
Protein tagged E1-A226V virus was 100 times more infective to Ae.
albopictus than it was to Ae. aegypti [4]. In all the Indian Ocean
Islands, Ae. albopictus became the main vector for CHIKV within
1–2 y after CHIKV was introduced to the region [31].
Of note is that Ae. aegypti has most likely been established in
North America for over 300 y, while Ae. albopictus has been in
many areas of the US, since 1985, primarily in Florida [32] and
since then has expanded its range in the country. Reiskind et al. set
out to determine if Ae. aegypti and Ae. albopictus mosquitoes captured
in Florida were susceptible to CHIKV infection by a La Reunion
isolate [32]. Each mosquito tested was highly susceptible to
infection by a full-length infectious clone of the La Re ´union Island
isolate, CHIKV LR2006 OPY1 strain. Even though the Ae.
albopictus strains were more susceptible to infection, overall ecology
and differences in human biting patterns need to be studied further
Figure 2. Life cycle of Chikungunya virus inside infected cells. Characteristically, there are two rounds of translation: (+) sense genomic RNA
(49S9=11.7 kb) acts directly as mRNA and is partially translated (59 end) to produce non-structural proteins (nsp’s). These proteins are responsible for
replication and formation of a complementary (2) strand, the template for further (+) strand synthesis. Subgenomic mRNA (26 S=4.1 kb) replication
occurs through the synthesis of full-length (2) intermediate RNA, which is regulated by nsp4 and p123 precursor in early infection and later by
mature nsp’s. Translation of the newly synthesized sub-genomic RNA results in production of structural proteins such as Capsid and protein E2-6k-E1
(from 39 end of genome). Assembly occurs at the cell surface, and the envelope is acquired as the virus buds from the cell and release and maturation
almost simultaneous occurred. Replication occurs in the cytoplasm and is very rapid (,4 h) [28,29].
doi:10.1371/journal.pntd.0000623.g002
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epidemic in the US [32].
Vertical Transmission
During the 7 d preceding birth, no human mother has been
reported to transmit the disease vertically. However, about 50% of
newborns delivered while the mother was infected with CHIKV
contracted the disease from their mother, despite the method of
delivery. Furthermore, there have been instances of CHIKV
transmission from mother to fetus causing congenital illness and
fetal death [33].
During the 2005–2006 La Reunion Island outbreaks, Ramful et
al. discovered that mothers could transmit CHIKV to their
progeny during the perinatal period (Day 24 to Day +1) [33,34],
and it is associated with a high degree of morbidity. By mean Day
4 of life, all of the neonates were symptomatic for CHIKV,
exhibiting common CHIKF symptoms. Six neonates were
confirmed to have contracted CHIKV and developed mengoen-
cephalitis. Of those mothers who, during the La Reunion Island
epidemic, were infected long before delivery, only three fetal
deaths were reported [12,33]. Ramful et al. theorized that mother-
to-child transmission most likely happens transplacentally shortly
before delivery [33]. A similar study by Gerardin et al. reported
nineteen cases of neonatal infection associated with intrapartum
maternal viremia that progressed to develop encephalitis owing to
vertical transmission from infected mothers [34].
CHIKV Diagnosis
Clinical and epidemiological similarities with dengue fever make
CHIKV diagnosis difficult, which may lead physicians to
misdiagnose CHIKV as dengue fever; therefore, the incidence of
CHIKV may actually be higher than currently believed (Table 1)
[6,12,35].
The amount of time elapsed since disease onset is the most
critical parameter when choosing a diagnostic test. CHIKV can be
detected and isolated by culturing with mosquito cells (C6/36),
Vero cells (mammalian), or in mice [26]. However, this method
can take at least a week and only achieves a high sensitivity during
the viremic phase, which usually only lasts up to 48 h after the
bite. Five days post-infection, the viral isolation approach has a
low sensitivity but is still the preferred method for detecting the
CHIKV strain [12,26,31,35]. RT-PCR on the other hand is a
faster and more sensitive method that can be used within the first
week of disease onset [26], and it is currently the most sensitive
method for detecting and quantifying viral mRNA [4,36].
Classic serological detection, by assays such as ELISA [37],
immunofluorescence [5,38], complement binding, and haemag-
glutination inhibition [39], constitutes the second diagnostic tool
used for biological diagnosis of CHIKV infection. These proven
techniques are useful for detection of Antigen in mosquitoes
during epidemiological studies. These assays detect virus-specific
IgM and IgG, however the sensitivity and specificity of these assays
has been poorly characterized. Viral competence, or the potential
of viral infection and transmission, is an important parameter that
can be quantified by ELISA, viral culture, and PCR.
A study by Ng et al. showed biomarkers indicative of severe
CHIKV infection [40]. They found decreased levels of RANTES
and increased levels of Interleukin-6 (IL-6) and Interleukin-1b (IL-
1b) that could be sued for CHIKV detection in patients as
indicators of CHIKV-driven cytokine storm. Couderc et al.
demonstrate another cytokine, type-I IFN, as a key player in the
progression to CHIKV infection [26]. Using an IFN-a/b null
mouse model, they demonstrated evidence of muscles, joints, and
skin as privileged CHIKV targets, which is consistent with human
pathology. Although Ng et al. concluded that RANTES levels
were significantly suppressed in severe CHIKF patients [40],
interestingly, an increase in levels of RANTES has been observed
in dengue infection [41]. Since the symptoms of CHIKF mimic
those of dengue fever, results obtained from this study strongly
suggest that RANTES could be a potential distinctive biomarker
that differentiates between these two clinically similar diseases.
Vaccine Approach against CHIKV Infection
There are no approved antiviral treatments currently available
for CHIKV [1,3,12,42]. Currently, CHIKF is treated symptom-
atically, usually with non-steroidal anti-inflammatory drugs or
steroids, bed rest, and fluids. Movement and mild exercise are
thought to decrease stiffness and morning arthralgia, but heavy
exercise may exacerbate rheumatic symptoms. Corticosteroids
may be used in cases of debilitating chronic CHIKV infection.
There is a debate about the appropriateness of chloroquine as
treatment for unresolved, non-steroidal anti-inflammatory drug-
resistant arthritis [43]. A study showed that viral production was
Table 1. Comparison of clinical features of Chikungunya and Dengue virus.
Clinical Features Chikungunya Virus (CHIKV) Dengue Virus (DENV) Reference
1) Fever, asthenia Common Common [6,8]
2) Myalgia Possible Very common [6]
3) Polyarthritis Very Common, edematous None [56]
4) Tenosynovitis Yes None [57]
5) Leukopenia None Yes [58]
6) Thrombocytopaenia None Yes [59]
7) Rash Days 1–4, important skin edema Days 3–7 [6,35,58]
8) Retro-orbital pain Rare Common [60]
9) Hypotension Possible Common, Days 5–7 [60,61]
10) Minor bleeding Chronic polyarthritis up to 1 year Common [17,56]
11) Second stage Possible; Tenosynvovitis at M2–M3 Raynaud’s
syndrome at M2–M3
Fatigue up to 3 mo [6,56,57,58,62,63]
doi:10.1371/journal.pntd.0000623.t001
www.plosntds.org 4 April 2010 | Volume 4 | Issue 4 | e623drastically reduced at 16 h post-infection after treatment with
100 mM dec-RVKR-cmk (Decanoyl-Arg-Val-Lys-Arg-chloro-
methylketone), a furine inhibitor [42,44]. Chloroquine acted by
raising the pH, blocking low pH-dependent entry of virus into the
cell. It is important to note that dec-RVKR-cmk or chloroquine
only inhibited viral spreading from cell to cell, not CHIKV
replication once it had entered the cell [43].
However, most would agree that the best weapon against
CHIKV is prevention. A live CHIKV vaccine developed by the
United States reached phase II clinical trial encompassing 59
healthy volunteers [45]. Eight percent of the volunteers experi-
enced transient arthralgia, while 98% of the volunteers had
seroconversion [45]. However, live CHIKV vaccines are still
questionable. One cannot discount the risk of a live vaccine
possibly inducing chronic rheumatism. Also, there is the question
as to whether widespread use among the public could trigger
mosquito transmission or lead to chronic infection or viral
reversion [1].
An alternative approach would be to produce a chimeric
vaccine against CHIKV. Wang et al. developed a chimeric
alphavirus vaccine that is uniformly attenuated and does not
cause reactogenicity in mice [3]. Three different versions of this
vaccine were made using three different backbone vectors:
Venezuelan equine encephalitis virus (VEEV) attenuated vaccine
strain T-83, naturally attenuated eastern equine encephalitis virus
(EEEV), and attenuated Sindbis virus (SINV). In short, CHIKV
structural proteins were engineered into the backbones of the
aforementioned vaccines to produce the chimeras [3]. These
chimeras were found to stimulate a strong humoral immunity,
and even at doses of 5.3–5.8 log10 PFU, they did not trigger
reactogenicity. When vaccinated mice were challenged with
CHIKV, neither adult nor neonatal mice gained weight, had
fever, or displayed signs of neurological illness. Upon comparison
of the chimeras with the Army181/25 vaccine, the Army vaccine
resulted in higher levels of viremia and replication in the joints of
neonatal mice. Because the joints are known targets of CHIKV,
Wang et al. noted their vaccine might avoid the negative
reactogenic side effects of the Army vaccine. After being
subcutaneously vaccinated with 5.3–5.8 log10 PFU of the
chimeric vaccines, mice produced strong neutralizing antibody
titers. The VEEV and EEEV chimeras yielded higher neutral-
izing antibody titers than the SINV chimera without being more
virulent. On top of this, the VEEV and EEEV CHIKV chimeras
seemed to be more immunogenic than the Army vaccine despite
the chimeras’ lower viremia and replication in the joints of
neonatal mice [3].
Tiwari et al. [46] adopted a different strategy using formalin
inactivated CHIKV in combination with alhydrogel (Aluminum
Hydroxide) as an adjuvant. This study clearly suggests that this
vaccine elicits both humoral and cell-mediated immune responses
in mice, providing its immunogenic potential. A recent study by
Couderc et al. [47] showed passive immunization as a potential
treatment for CHIKV infection. Using purified immunoglobulin
extracted from convalescent CHIKV patients, they demonstrated
effective neutralizing activity against CHIKV infection both in
vitro and in vivo. This thereby establishes a potential preventive
and therapeutic approach to combat CHIKV infection. Patho-
genesis studies conducted with related alpha virus, like RRV, have
shown the role of macrophages in persistence on infection [48].
They also demonstrated the role of RRV-specific CD8 T cells in
clearing viral load in infected patients, thereby warranting similar
investigations with CHIKV and the importance of investigating a
cell-mediated immune response-based vaccine against CHIKV
[49].
There are always certain risks associated with live attenuated or
inactivated viral vaccines [50]. One way to avoid these potential
problems is to construct a consensus-based DNA vaccine. DNA
based vaccines have an improved safety profile as compared to live
or attenuated vaccines [51,52]. A consequence of CHIKV’s rapid
evolution is difficulty in constructing a vaccine that will be able to
Figure 3. Levels of CHIKV-specific IgG in mice immunized with CHIKV vaccines. Each group of C57BL/6 mice (n=5) was immunized with
12.5 mg of pVax1 control vector or CHIKV vaccine plasmids as indicated at 0 and 2 wk. Mice were bled 2 wk after each immunization, and each
group’s serum pool was diluted to 1:100 and 1:500 for reaction with specific vaccine constructs. Serum was incubated for 1 h at 37uC on 96-well
plates coated with 2 mg/ml of respective CHIKV peptides, and antibody was detected using anti-mouse IgG-HRP and OD was measured at 405 nm.
doi:10.1371/journal.pntd.0000623.g003
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virus. One of the strengths of DNA consensus vaccines is its ability
to induce cross-reactive immune responses against the three
distinct phylogenetic groups of CHIKV. Also DNA-based vaccines
can be produced more rapidly than protein-based vaccines.
Recently, Muthumani et al. constructed a vaccine that was
shown to induce both humoral and cellular immunity in vivo in
3–4-wk-old female C57/BL6 mice [49]. These mice were
immunized using an in vivo electroporation method to deliver
the vaccine into the quadriceps muscle. The consensus construct
was designed against E1, E2, and the core protein capsid. To
design the construct, they aligned 21 sequences of CHIKV
isolated between 1952 and 2006, using strains from differing
countries, including La Reunion Island. The most common
nucleotide among the sequences was chosen at each position to
be used in the consensus construct, taking care not to alter the
reading frame. They conducted codon and RNA optimization,
added a strong Kozak sequence, and substituted signal peptide
with an immunoglobulin E leader sequence to improve vaccine
efficacy.
After immunizing the mice, spleens were harvested along with
serum and tested to determine antibody titer. After three
immunizations, consensus E1, E2, and C vaccines were shown
to induce T-cell immune responses leading to strong IFN-c
responses and proliferation in C57/BL6 mice. Furthermore, when
compared with control mice, immunized mice had higher total
IgG levels as well as higher anti-E1 specific, anti-E2 specific, and
anti-C specific IgG antibodies, suggesting a strong humoral
immune response (Figure 3) and also specificity for the antigens
encoded in the vaccine constructs (Figure 4). Because of its
promising results and the need for a safer vaccine, this consensus
DNA vaccine deserves further investigation. Determining longev-
ity of protective effects of the vaccine and persistence of antibody
and IFN-c responses could be the next step of investigation.
Challenged studies of immunized mice must also be carried out.
Conclusion
CHIKV mosquito-borne disease has caused massive outbreaks
for at least half a century but is no longer confined to the
Figure 4. DNA vaccinated mice are capable of producing antibodies against the antigens encoded in the DNA vaccine. Hela cells
transfected with DNA plasmid vaccine encoding the CHIKV Capsid (left) and Envelope (right) genes were examined for protein expression using
confocal microscopy. Serum collected from mice immunized with the DNA vaccine was used as the primary antibody for detection of CHIKV proteins.
Two days post-transfection, the cells, treated with serum and then with an anti-mouse IgG conjugated with Alexa-Fluor 488, were visualized under
the Ziess LSM510 META NLO Laser Scanning Confocal Microscope (663). Expression of high levels of CHIKV proteins in these cells revealed the
presence of CHIKV-specific antibodies, thereby validating the efficacy of the DNA vaccine in inducing antibodies.
doi:10.1371/journal.pntd.0000623.g004
Table 2. Comparative properties of DNA vaccines over other vaccine approaches.
Property Live Attenuated Virus Killed Viral Particle DNA Vaccine Reference
Manufacture & design Laborious design process Simpler process but requires
meticulous monitoring of process
parameters to conserve potency
Simple molecular genetic processes involved
in manufacturing and plasmid optimization
[52]
Cell-mediated responses Good Poor High [53,64,65]
Antibody responses Mainly IgG IgA and IgG No significant antibody response [53]
Safety Possible reversion to virulence Lesser likelihood of reversion No possibility of virulence or toxicity reported [52,66]
Duration of immunity Many years Lesser duration Long-term immunogen persistence [52,54,65]
Post-manufacturing
stability
Requires continuous cold chain
sustenance
Requires preserving in cold chain as
it is heat liable
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the developing world. As a result, the NIAID has designated
CHIKV as a Category C pathogen alongside the influenza and
SARS-CoV viruses [3]. Realization of the potential severity of this
disease is exigent; for instance, if used as a biological weapon, the
world economy could be severely crippled; if enough members of
the armed forces were to become infected during a military
deployment, military operations could be significantly affected.
Efforts to monitor the disease will only provide minimal warning in
a global society, and steps to prevent the morbidity and mortality
associated with pandemic are imperative [21,31].
Despite the gravity of its infectious potency and the fear of it
being a potential biological weapon, there is currently no vaccine
for CHIKV infections. Live attenuated vaccine trials were carried
out in 2000, but funding for the project was discontinued. Newer
approaches such as DNA vaccines appear promising over
conventional strategies like live attenuated or inactivated virus
and thus call for further investigation. Recent advances such
electroporation delivery and incorporation of adjuvants has
boosted DNA vaccine efficacy [51,53]. Despite the low antibody
response to DNA vaccines, other numerous advantages have
overshadowed these minor drawbacks (Table 2), the most
important one being the ability to induce both humoral and
cellular immune responses [51,54].
Judging by recent success, such as the immunogenic construct
developed by Muthumani et al., DNA vaccines could play a major
role in combating CHIKV [49]. Vaccines are literally a critical
component of CHIKV disease control and therefore research in
this area is highly encouraged. The dramatic spread of dengue
viruses (DENV) throughout tropical America since 1980 via the
same vectors and human hosts underscores the risk to public
health in the Americas. The adverse events associated with the
current live vaccine are well documented [55]. Realizing these
drawbacks, earnest efforts should be taken to develop new
strategies to forestall further spread and complications.
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